Further, the genetic deletion of SLC7A11 in various preclinical tumor models acts synergistically with immune checkpoint immunotherapeutic agents, such as anti-CTLA4, to suppress tumor growth (109). This evidence concerns the gene CTLA4 and neoplasm.